Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aravive, Inc.
Genmab Accelerates Priority Candidates, Ends Enapotamab Vedotin Development
Denmark’s biotech Genmab has dropped the AXL targeted antibody-drug conjugate, enapotamab vedotin from early clinical development, and is focusing its resources on other therapeutic programs.
Asia Deal Watch: LianBio Partners With Pfizer In Greater China, Gets Financial Backing
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.
Pipeline Watch: Phase III Progress With Lefamulin, Dupilumab, Patisiran
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
VELOCITY Failure For Versartis's Lead Drug Sends Shares Into Tailspin
Versartis's long-acting growth hormone product missed Phase III non-inferiority endpoint, wiping more than 83% of the company's value.
- Large Molecule
- Other Names / Subsidiaries
- Aravive Biologics, Inc., Ruga Corporation, Versartis, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.